PDS Biotech Logo.png
PDS Biotech Announces Participation in the Channelchek Takeaway Series
26 janv. 2023 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
13 janv. 2023 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
03 janv. 2023 07h00 HE | PDS Biotechnology Corporation
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at...
PDS Biotech Logo.png
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
28 déc. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
15 déc. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
21 nov. 2022 08h00 HE | PDS Biotechnology Corporation
Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform Dr. Siva Gandhapudi, Director of...
PDS Biotech Logo.png
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 07h30 HE | PDS Biotechnology Corporation
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC...
PDS Biotech Logo.png
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
14 nov. 2022 07h00 HE | PDS Biotechnology Corporation
In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...
PDS Biotech Logo.png
PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)
07 nov. 2022 08h00 HE | PDS Biotechnology Corporation
Patients with high-risk, locally advanced cervical cancer on IMMUNOCERV demonstrated increased tumor-infiltrating polyfunctional CD8+ (killer) T cells, and 1-year overall survival of 100% Data from...
PDS Biotech Logo.png
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results
31 oct. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...